Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2004 • 3,873 citations

A small molecule–kinase interaction map for clinical kinase inhibitors

2005 • 1,854 citations

A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

2003 • 1,683 citations

The idiopathic hypereosinophilic syndrome

1994 • 928 citations

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

2004 • 855 citations

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

2005 • 556 citations

Targeted Therapy for Metastatic Renal Cell Carcinoma

2006 • 437 citations

Discovery of a novel Raf kinase inhibitor.

2001 • 417 citations

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

2003 • 395 citations

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

2003 • 388 citations

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

2005 • 328 citations

Treatment of hypereosinophilic syndrome with imatinib mesilate

2002 • 310 citations

Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680

2006 • 278 citations

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

2003 • 219 citations

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

2003 • 203 citations

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

2005 • 193 citations

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

2006 • 187 citations

Targeted therapy for metastatic renal cell carcinoma

2006 • 141 citations

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA

2002 • 140 citations

Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors

2004 • 137 citations

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR and FIP1L1-PDGFR in vitro and in vivo

2005 • 115 citations

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA–positive chronic eosinophilic leukemia

2003 • 87 citations

Resistance to tyrosine kinase inhibitors: Calling on extra forces

2005 • 40 citations

The idiopathic hypereosinophilic syndrome and eosinophilic leukemias.

2004 • 27 citations